Passage Bio is committed to transforming lives
We focus on developing effective treatments that are desperately needed for central nervous system (CNS) disorders. Visit one of the sites below to learn more about the potential treatments we are studying in clinical trials.
Passage Bio is studying a potential new therapy for the treatment of frontotemporal dementia (FTD) caused by a GRN mutation.
If you are a patient or caregiver and want to learn more, visit FTDClinicalTrial.com.
If you are a healthcare professional and want to learn more, visit FTDClinicalTrial-hcp.com.
Passage Bio is studying a potential new therapy for the treatment of GM1 gangliosidosis.
Learn more about the potential treatment, understand more about GM1 gangliosidosis, and connect with support and resources at GM1Study.com.